Cancer Development and Progression

Mei He, Jennifer Rosen, David Mangiameli, Steven K. Libutti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cancer development and progression is a complex process that involves a host of functional and genetic abnormalities. Genomic perturbations and the gene expression they lead to, can now be globally identified with the use of DNA microarray. This relatively new technology has forever changed the scale of biological investigation. The enormous amount of data generated via a single chip has led to major global studies of the cellular processes underlying malignant transformation and progression. The multiplicity of platforms from different proprietors has offered investigators flexibility in their experimental design. Additionally, there are several more recent microarrays whose designs were inspired by the nucleotide-based technology. These include protein, multi-tissue, cell, and interference RNA microarrays. Combinations of microarray and other contemporary scientific methods, such as, laser capture microdissection (LCM), comparative genomic hybridization (CGH), single nude-otide polymorphism analysis (SNP) and chromatin immunoprecipitation (ChIP), have created entirely new fields of interest in the more global quest to better define the molecular basis of malignancy. In addition to basic science applications, many clinical inquiries have been performed. These queries have shown microarray to have clinical utility in cancer diagnosis, risk stratification, and patient management.

Original languageEnglish (US)
Pages (from-to)117-133
Number of pages17
JournalAdvances in Experimental Medicine and Biology
Volume593
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Microarrays
Laser Capture Microdissection
Technology
Neoplasms
Comparative Genomic Hybridization
Chromatin Immunoprecipitation
RNA Interference
Oligonucleotide Array Sequence Analysis
Microdissection
Research Design
Nucleotides
Research Personnel
Gene Expression
Polymorphism
Gene expression
Design of experiments
Chromatin
RNA
Tissue
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cancer Development and Progression. / He, Mei; Rosen, Jennifer; Mangiameli, David; Libutti, Steven K.

In: Advances in Experimental Medicine and Biology, Vol. 593, 2007, p. 117-133.

Research output: Contribution to journalArticle

He, Mei ; Rosen, Jennifer ; Mangiameli, David ; Libutti, Steven K. / Cancer Development and Progression. In: Advances in Experimental Medicine and Biology. 2007 ; Vol. 593. pp. 117-133.
@article{d178539a08b34e289a471ecd9bcf6315,
title = "Cancer Development and Progression",
abstract = "Cancer development and progression is a complex process that involves a host of functional and genetic abnormalities. Genomic perturbations and the gene expression they lead to, can now be globally identified with the use of DNA microarray. This relatively new technology has forever changed the scale of biological investigation. The enormous amount of data generated via a single chip has led to major global studies of the cellular processes underlying malignant transformation and progression. The multiplicity of platforms from different proprietors has offered investigators flexibility in their experimental design. Additionally, there are several more recent microarrays whose designs were inspired by the nucleotide-based technology. These include protein, multi-tissue, cell, and interference RNA microarrays. Combinations of microarray and other contemporary scientific methods, such as, laser capture microdissection (LCM), comparative genomic hybridization (CGH), single nude-otide polymorphism analysis (SNP) and chromatin immunoprecipitation (ChIP), have created entirely new fields of interest in the more global quest to better define the molecular basis of malignancy. In addition to basic science applications, many clinical inquiries have been performed. These queries have shown microarray to have clinical utility in cancer diagnosis, risk stratification, and patient management.",
author = "Mei He and Jennifer Rosen and David Mangiameli and Libutti, {Steven K.}",
year = "2007",
doi = "10.1007/978-0-387-39978-2_12",
language = "English (US)",
volume = "593",
pages = "117--133",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Cancer Development and Progression

AU - He, Mei

AU - Rosen, Jennifer

AU - Mangiameli, David

AU - Libutti, Steven K.

PY - 2007

Y1 - 2007

N2 - Cancer development and progression is a complex process that involves a host of functional and genetic abnormalities. Genomic perturbations and the gene expression they lead to, can now be globally identified with the use of DNA microarray. This relatively new technology has forever changed the scale of biological investigation. The enormous amount of data generated via a single chip has led to major global studies of the cellular processes underlying malignant transformation and progression. The multiplicity of platforms from different proprietors has offered investigators flexibility in their experimental design. Additionally, there are several more recent microarrays whose designs were inspired by the nucleotide-based technology. These include protein, multi-tissue, cell, and interference RNA microarrays. Combinations of microarray and other contemporary scientific methods, such as, laser capture microdissection (LCM), comparative genomic hybridization (CGH), single nude-otide polymorphism analysis (SNP) and chromatin immunoprecipitation (ChIP), have created entirely new fields of interest in the more global quest to better define the molecular basis of malignancy. In addition to basic science applications, many clinical inquiries have been performed. These queries have shown microarray to have clinical utility in cancer diagnosis, risk stratification, and patient management.

AB - Cancer development and progression is a complex process that involves a host of functional and genetic abnormalities. Genomic perturbations and the gene expression they lead to, can now be globally identified with the use of DNA microarray. This relatively new technology has forever changed the scale of biological investigation. The enormous amount of data generated via a single chip has led to major global studies of the cellular processes underlying malignant transformation and progression. The multiplicity of platforms from different proprietors has offered investigators flexibility in their experimental design. Additionally, there are several more recent microarrays whose designs were inspired by the nucleotide-based technology. These include protein, multi-tissue, cell, and interference RNA microarrays. Combinations of microarray and other contemporary scientific methods, such as, laser capture microdissection (LCM), comparative genomic hybridization (CGH), single nude-otide polymorphism analysis (SNP) and chromatin immunoprecipitation (ChIP), have created entirely new fields of interest in the more global quest to better define the molecular basis of malignancy. In addition to basic science applications, many clinical inquiries have been performed. These queries have shown microarray to have clinical utility in cancer diagnosis, risk stratification, and patient management.

UR - http://www.scopus.com/inward/record.url?scp=84934441284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934441284&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-39978-2_12

DO - 10.1007/978-0-387-39978-2_12

M3 - Article

AN - SCOPUS:84934441284

VL - 593

SP - 117

EP - 133

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -